Lyell Immunopharma Price Target Lowered to 60c From $1 at BofA

TipRanksJan 12 06:20 ET

BofA Securities Downgrades Lyell Immunopharma(LYEL.US) to Sell Rating, Cuts Target Price to $0.6

Moomoo NewsJan 11 11:32 ET · Ratings

Lyell Immunopharma Accelerates Development of IMPT-314 for Large B-Cell Lymphoma, Discontinues LYL119 Program to Focus Resources

Quiver QuantitativeJan 9 09:11 ET

Lyell to Highlight Vision for Its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

GlobeNewswireJan 9 09:00 ET

Bank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)

TipRanksJan 6 06:37 ET · Ratings

Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4

Moomoo NewsDec 24, 2024 08:32 ET · Ratings